Brief: Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for multiple myeloma treatment
12/04/2017 12:31
April 12 (Reuters) - Active Biotech Ab ACTI.ST
* Reg-Active biotech: fda grants orphan drug designation for
tasquinimod for the treatment of multiple myeloma
Source text for Eikon: ID:nGNEbyGKvr
Further company coverage: ACTI.ST
(Reporting By Anna Ringstrom)
((Anna.Ringstrom@thomsonreuters.com;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million